Amicus Therapeutics (NASDAQ:FOLD) Insider Sells $282,073.00 in Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider David Michael Clark sold 25,643 shares of the stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $11.00, for a total value of $282,073.00. Following the completion of the transaction, the insider directly owned 271,332 shares of the company’s stock, valued at $2,984,652. This represents a 8.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

David Michael Clark also recently made the following trade(s):

• On Monday, November 24th, David Michael Clark sold 25,643 shares of Amicus Therapeutics stock. The shares were sold at an average price of $10.10, for a total value of $258,994.30.
• On Tuesday, November 4th, David Michael Clark sold 25,643 shares of Amicus Therapeutics stock. The stock was sold at an average price of $9.51, for a total value of $243,864.93.

Amicus Therapeutics Stock Performance

Shares of FOLD stock opened at $14.20 on Friday. The company’s fifty day moving average price is $9.48 and its 200-day moving average price is $7.82. The stock has a market cap of $4.38 billion, a PE ratio of -354.81 and a beta of 0.46. The company has a current ratio of 2.99, a quick ratio of 2.09 and a debt-to-equity ratio of 1.70. Amicus Therapeutics, Inc. has a 12 month low of $5.51 and a 12 month high of $14.36.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.05. Amicus Therapeutics had a negative net margin of 2.35% and a positive return on equity of 6.95%. The company had revenue of $169.06 million during the quarter, compared to analyst estimates of $165.24 million. During the same period last year, the business earned $0.10 EPS. Amicus Therapeutics’s quarterly revenue was up 19.5% compared to the same quarter last year. On average, equities analysts expect that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.

Trending Headlines about Amicus Therapeutics

Here are the key news stories impacting Amicus Therapeutics this week:

• Positive Sentiment: BioMarin to acquire Amicus for ~$4.8B ($14.50 per share), citing complementary marketed products (Galafold, Pombiliti + Opfolda), $599M of recent revenue and expectations the deal will be accretive to non‑GAAP EPS within 12 months — this provides a clear exit price and strategic rationale that pushed the stock up. Article Title
• Positive Sentiment: BioMarin’s press release emphasizes revenue upside from bringing Amicus products into BioMarin’s global footprint and resolving pending patent litigation on Galafold — details that support the acquisition valuation and near-term revenue accretion view. Article Title
• Neutral Sentiment: Trading was temporarily halted pre-market for “news pending,” then resumed around the acquisition announcement — a procedural sign the market treated the item as material. (Trading halt noted in market alerts.)
• Neutral Sentiment: Cantor Fitzgerald reaffirmed a “neutral” rating with a $14.50 price target (roughly in line with the deal price), and Needham reiterated a “hold” — analyst stances imply limited upside beyond the announced offer price absent a competing bidder. Article Title
• Negative Sentiment: Two investor‑rights firms (Halper Sadeh LLC and The Ademi Firm) announced investigations into whether the $14.50 per‑share sale is fair to Amicus shareholders — litigation or proxy fights could delay closing, pressure timing, or open the door to a higher bid/renegotiation, increasing deal execution risk. Article Title
• Negative Sentiment: Insider selling disclosures (including recent sales by the CEO and another officer) surfaced in filings earlier this week — while not unusual, these sales add a note of caution for some investors evaluating management alignment ahead of the deal. Article Title

Institutional Investors Weigh In On Amicus Therapeutics

Several institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its position in Amicus Therapeutics by 0.4% in the 3rd quarter. Vanguard Group Inc. now owns 29,534,029 shares of the biopharmaceutical company’s stock worth $232,728,000 after buying an additional 126,441 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Amicus Therapeutics by 2.6% in the first quarter. Wellington Management Group LLP now owns 29,200,617 shares of the biopharmaceutical company’s stock worth $238,277,000 after acquiring an additional 738,623 shares during the period. William Blair Investment Management LLC raised its holdings in shares of Amicus Therapeutics by 7.6% during the third quarter. William Blair Investment Management LLC now owns 15,749,240 shares of the biopharmaceutical company’s stock valued at $124,104,000 after purchasing an additional 1,107,083 shares during the last quarter. Vestal Point Capital LP lifted its position in Amicus Therapeutics by 178.4% during the second quarter. Vestal Point Capital LP now owns 11,900,000 shares of the biopharmaceutical company’s stock valued at $68,187,000 after purchasing an additional 7,625,000 shares during the period. Finally, State Street Corp boosted its holdings in Amicus Therapeutics by 21.5% in the second quarter. State Street Corp now owns 11,568,097 shares of the biopharmaceutical company’s stock worth $66,285,000 after purchasing an additional 2,049,078 shares during the last quarter.

Analyst Ratings Changes

Several research firms recently weighed in on FOLD. Cantor Fitzgerald restated a “neutral” rating and issued a $14.50 price target (down previously from $21.00) on shares of Amicus Therapeutics in a research note on Friday. Zacks Research raised Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. The Goldman Sachs Group raised their price target on Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research note on Friday. Finally, JPMorgan Chase & Co. raised their price objective on shares of Amicus Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $16.36.

Amicus Therapeutics Company Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.